Search

Sadly, Dr Jim Hu, a founding member of the Center for Phage Technology at Texas A&M University, has passed away. He was great scientist, dedicated mentor, and valued member of CPT and TAMU. — Center for Phage Technology, Twitter Jim was pa

When doing a PEG precipitation of phages, some people (like me) use a PEG stock solution (20-30% w/v PEG in NaCl), whereas other people add the PEG powder directly to the sample. What are the pros and cons? — @EvelienAdri Check out the Twi

When doing a PEG precipitation of phages, some people (like me) use a PEG stock solution (20-30% w/v PEG in NaCl), whereas other people add the PEG powder directly to the sample. What are the pros and cons? — @EvelienAdri Check out the Twi

Sadly, Dr Jim Hu, a founding member of the Center for Phage Technology at Texas A&M University, has passed away. He was great scientist, dedicated mentor, and valued member of CPT and TAMU. — Center for Phage Technology, Twitter Jim was pa

Phages are extremely diverse at the genetic level, but not so much at the structural level... why? In an informative new review, Moïra Dion (Université Laval, Canada) and colleagues have explored phage diversity at the structural, genomic a

Listen to Jeremy Barr of Monash University's take on phage therapy and how close we are to bringing it to patients at scale. 16 min.

Lance Boling (SDSU) and colleagues tested 117 consumable compounds (like toothpaste, Stevia, aspartame) for their ability to induce prophages from four bacterial species. They found that certain compounds induced prophages (some in a specie

A new monthly podcast called Superbugs Unplugged covers antimicrobial resistance news (and even covers phages, in episode two!).

Aurélie Mathieu (Université Paris-Saclay) and colleagues have published an exciting new paper in Nature Communications: they isolated 150 E. coli phages from fecal samples from 1-year-old infants. Then they analyzed the host range of the ph

Australia is becoming a hotspot for phage therapy research and innovation. In this in-depth Sydney Morning Herald feature, Jeremy Barr describes his role in Tom Patterson's phage therapy case (Jeremy now runs his own phage research lab at M

Could destroying phages after they've found their target help make phages work more like drugs? In a new PNAS paper, Huan Peng (UC Santa Barbara) and colleagues describe how they've conjugated phages to gold nanorods, which can "cook" nearb

A new crAssphage paper by Tanvi Honap (University of Oklahoma) and colleagues shows that crAssphage prevalence correlates with more industrialized lifestyles. Paper | News Article

BCM Tailor Labs is a new initiative out of Baylor College of Medicine focused on phage therapy.

Attention phage companies with interests in addressing animal health challenges! You can apply here to showcase your solution at the Animal Microbiome and Nutritional Health Congress in Chicago Mar 3-4, 2020. (Apparently most companies who'

A new article in STAT News by Eric Boodman (one of our favourite phage journalists!) talks about how a phage has been found that kills Mallory Smith's infective Burkholderia cepacia isolate. In Mallory's honour, the phage has been named BCM

BCM Tailor Labs is a new initiative out of Baylor College of Medicine focused on phage therapy.

We know a lot about how phages expand their host ranges, but not so much about how they shrink them. A new Scientific Reports paper by Tzvi Holtzman (Israel Institute for Biological Research) and colleagues shows how T7 phage limits futile

A new crAssphage paper by Tanvi Honap (University of Oklahoma) and colleagues shows that crAssphage prevalence correlates with more industrialized lifestyles. Paper | News Article

Could destroying phages after they've found their target help make phages work more like drugs? In a new PNAS paper, Huan Peng (UC Santa Barbara) and colleagues describe how they've conjugated phages to gold nanorods, which can "cook" nearb

PhagoMed attended the Biotech Showcase 2020 this week in San Francisco, and announced it is looking to raise $16 million from US and European investors to bring its phage products to the clinic (watch this interview with CEO Alexander Belcr